Patheon launches latest industry programme
A global provider of drug development and manufacturing services to the pharmaceutical sector has launched its newest industry programme.
A global provider of drug development and manufacturing services to the pharmaceutical sector has launched its newest industry programme.
Patheon's "Quick To Market" programme offers accelerated transfer of commercially available products from an existing manufacturing plant to a plant within Patheon's network.
The programme supplements Patheon's already established "Quick to Clinic' programme, which accelerates the development of early stage molecules at pre-clinical status and allows rapid distribution of drug product for use in Phase 1 clinical studies.
The Quick To Market programme also introduces its '4-6-8 Promise' - which emphasises to clients how quickly the work can be done by Patheon.
The 4-6-8 can be broken down into the following:
4: Quick To Clinic(SM) solid dose molecules will be formulated and ready for distribution to phase 1 clinical trials in just four months from receipt of API.
6: Quick To Market(SM) solid dose or liquid products will be transferred and ready for regulatory filing in just six months from receipt of analytical methods and API. This enables clients to move products very quickly out of their plants and facilitate rationalisation programmes.
8: Quick To Market aseptic liquid or lyophilized sterile products will be ready for regulatory filing in just eight months from receipt of analytical methods and API.